Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00710697
Recruitment Status : Unknown
Verified September 2009 by Poniard Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : July 4, 2008
Last Update Posted : September 24, 2009
Information provided by:
Poniard Pharmaceuticals

Brief Summary:
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: Picoplatin Phase 1

Detailed Description:

Phase 1 and 2 studies have demonstrated that picoplatin, a next-generation platinum analogue designed to avoid drug resistance, has activity when administered IV in a variety of cancers. Preclinical and clinical studies indicate that picoplatin may be effective in platinum refractory or resistant cancer.

Preclinical data in beagle dogs have shown that picoplatin had no effect on cardiovascular function, including the QT interval. In the cumulative human trial experience, the cardiovascular serious adverse events that have occurred are consistent with events expected in patients with advanced malignant disease and do not suggest any propensity toward drug-related serious ventricular arrhythmias or sudden death.

The purpose of this trial is to conduct a formal study to specifically evaluate the effect of picoplatin on the QT/QTc interval as measured by the ECG, and to correlate QTcF interval with plasma total and ultrafilterable platinum concentrations. This study is also being conducted to ensure the safety of picoplatin with regard to the QT/QTc interval. Patients who choose to participate in this study will also be given the opportunity to continue to receive picoplatin until limited by toxicity or disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Picoplatin in Subjects With Advanced Non-Hematological Malignancies With Emphasis on Cardiac Repolarization
Study Start Date : June 2008
Estimated Primary Completion Date : March 2009
Estimated Study Completion Date : July 2009

Arm Intervention/treatment
Experimental: Single Arm
Drug: Picoplatin
IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Primary Outcome Measures :
  1. ECG interval change [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Safety/Efficacy [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented histological or cytological diagnosis of non-hematological malignancy.
  • Subjects for whom, in the opinion of the investigator, treatment with single agent picoplatin is appropriate.
  • 18 years of age or older.
  • ECOG performance status 0-2.
  • An acceptable screening ECG.
  • The following laboratory values:
  • ANC ≥ 1500 cells/mm3 (without use of myeloid growth factors).
  • Hemoglobin ≥ 10.0 g/dL (may be achieved with transfusion or growth factors).
  • Platelet count ≥ 100,000/mm3 (without platelet transfusions in the past 10 days).
  • Serum creatinine ≤ 1.5 x ULN.
  • Total bilirubin ≤ 1.5 x ULN.
  • AST/SGOT and ALT/SGPT ≤ 2.5 x ULN (up to 5.0 x ULN in the event of documented hepatic tumor involvement).
  • Serum potassium and magnesium within institutional normal limits. PT, aPTT ≤ 1.2 x ULN.
  • Recovery period ≥ 4 weeks since major surgery, any chemotherapy (≥ 6 weeks for treatment with mitomycin or any nitrosourea), any biological therapy, any investigational therapy or any change in usage of "alternative therapies".
  • Recovery period ≥ 2 weeks since any radiation therapy.
  • Willing, available and able to comply with all protocol requirements including dietary schedule and restrictions.
  • Written informed consent obtained prior to any screening procedures.

Exclusion Criteria:

  • Symptomatic or uncontrolled brain metastases.
  • Use of conventional granulocyte growth factors within the preceding 10 days or pegfilgrastim within the past 21 days.
  • Any concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study. For example,
  • Unresolved toxicities from prior treatments of > Grade 1 (other than alopecia).
  • Clinically significant infection.
  • Known viral infections with hepatitis B or C or HIV.
  • Clinically significant psychiatric illness.
  • Any other systemic or localized disease or therapy likely to interfere with tolerance of chemotherapy or requirements of study participation.
  • History of unexplained syncope within the last two months or a family history of sudden unexplained death.
  • Cardiac contraindications to study participation, including:
  • History of serious cardiac disease, defined as myocardial infarction within three months of enrollment, congestive heart failure classified by the New York Heart Association as Class III or IV, clinically significant cardiac arrhythmias, poorly controlled or unstable angina or electrocardiographic evidence of acute ischemia.
  • Implantable pacemaker or automatic implantable cardioverter defibrillator.
  • Congenital long QT syndrome or family history of long QT syndrome.
  • If male, QTc > 450 ms; if female, QTc > 460 ms.
  • PR duration > 240 ms; QRS > 110 ms. Complex arrhythmias (significant ventricular tachycardia, Mobitz block, bifascicular AV block) on the screening ECG.
  • Atrial fibrillation or flutter. Complete left bundle branch block; use of an obligate pacemaker.
  • Current use of anticoagulants or anti-platelet drugs, including aspirin, warfarin, enoxaparin, clopidogrel, or heparin (use of heparin for central venous port maintenance is acceptable).
  • Ongoing bleeding or history of clinically significant bleeding within the last 6 months (unless the etiology of the prior bleeding has been identified and corrected).
  • Concurrent medications that prolong the QT interval (including cisapride, erythromycin, antipsychotics or tricyclic antidepressants, quinidine, procainamide, disopyramide, amiodarone or sotalol), or any agent classified as either "Drugs with Risk of Torsades de Pointes" or "Drugs with Possible Risk of Torsades de Pointes" on the website
  • Female subjects who are pregnant or breast feeding.
  • Subjects of reproductive potential not willing to use an effective method of contraception during the study (from first day of and until 1 month after study drug administration).
  • Conditions that may interfere with QTc analysis:
  • Allergy to ECG electrodes.
  • Any condition that impairs the placement of ECG electrodes or the interpretation of ECGs (including but not limited to breast implants).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00710697

Layout table for location information
United States, Arizona
Premiere Oncology of Arizona
Scottsdale, Arizona, United States, 85258
United States, California
Moores UCSD Cancer Center
La Jolla, California, United States, 92093
Premiere Oncology
Santa Monica, California, United States, 90404
United States, Georgia
Georgia Cancer Specialists
Atlanta, Georgia, United States, 30341
United States, New Mexico
UNM Cancer Center
Albuquerque, New Mexico, United States, 87131
United States, Washington
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Northwest Medical Specialities
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Poniard Pharmaceuticals
Layout table for investigator information
Study Director: Robert Earhart, MD, PhD Poniard Pharmaceuticals
Additional Information:
Layout table for additonal information
Responsible Party: Robert Earhart, MD, PhD, Poniard Pharmaceuticals Identifier: NCT00710697    
Other Study ID Numbers: 0701
First Posted: July 4, 2008    Key Record Dates
Last Update Posted: September 24, 2009
Last Verified: September 2009
Keywords provided by Poniard Pharmaceuticals:
Bladder Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Neoplasm
Head and Neck Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostrate Cancer